- Previous Close
0.0970 - Open
0.0930 - Bid 0.0990 x --
- Ask 0.1300 x --
- Day's Range
0.0930 - 0.0930 - 52 Week Range
0.0920 - 0.1440 - Volume
1,070 - Avg. Volume
400 - Market Cap (intraday)
163.74M - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
9.30 - EPS (TTM)
0.0100 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield 0.01 (10.95%)
- Ex-Dividend Date Jul 3, 2025
- 1y Target Est
--
PW Medtech Group Limited, an investment holding company, operates as a medical device company in China, India, North America, and internationally. It operates through three segments: Infusion Set Business; Blood Purification Business; and Regenerative Medical Biomaterials Business. The company manufactures and sells infusion sets, such as non-PVC-based infusion sets, precision filter infusion sets, light resistant infusion sets, intravenous cannula products, and insulin needles and pens; hemodialysis and blood purification medical devices; high flux hemodialyzers, low flux hemodialyzers, hemodiafilters, and hemoperfutors; and animal-derived regenerative medical biomaterials and human tissue repair alternative products. The company was formerly known as Pyholding Limited. PW Medtech Group Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
www.pwmedtech.com1,415
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: PWE.F
View MorePerformance Overview: PWE.F
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PWE.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PWE.F
View MoreValuation Measures
Market Cap
173.18M
Enterprise Value
-34.94M
Trailing P/E
7.66
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.50
Price/Book (mrq)
0.28
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
19.61%
Return on Assets (ttm)
2.11%
Return on Equity (ttm)
4.00%
Revenue (ttm)
768.9M
Net Income Avi to Common (ttm)
150.78M
Diluted EPS (ttm)
0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.69B
Total Debt/Equity (mrq)
0.25%
Levered Free Cash Flow (ttm)
--